This is a correction to: Fengna Chu, Mingchao Shi, Canyun Liu, Jie Zhu, Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody? Clinical and Experimental Immunology, Volume 213, Issue 3, September 2023, Pages 363–370, https://doi.org/10.1093/cei/uxad053
In the ‘Materials and Methods’ section, it is stated that anti-glial fibrillary acidic protein (GFAP) antibodies were detected. In fact, GFAP was detected.
Additionally, in the ‘Discussion’ section, the paragraph “But in our study, we did not find any GFAP increase either in AQP4 positive or negative groups. The inconsistent results may be caused by different detection methods, CBA method used in our study and ultrasensitive single-molecule array assays applied in the previous studies”, should be disregarded due to the process having detected anti-GFAP antibody, rather than detecting GFAP.
These emendations are outlined only within this notice to preserve the version of record.